⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7623278 | 0.62 | — | — | |
| SCHEMBL795389 | 0.56 | — | — | |
| SCHEMBL2020536 | 0.56 | — | — | |
| SCHEMBL24317548 | 0.56 | ADORA1 (0.39) | — | |
| SCHEMBL3708487 | 0.55 | ADORA1 (0.43) | — | |
| SCHEMBL1298710 | 0.55 | — | — | |
| SCHEMBL468257 | 0.55 | — | — | |
| SCHEMBL2282179 | 0.55 | — | — | |
| SCHEMBL2020534 | 0.55 | — | — | |
| SCHEMBL25047048 | 0.54 | L3MBTL1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079954-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-23 | — | — | US | claimed |
| US-9540351-B2 | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | claimed |
| EP-3046918-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2016-07-27 | — | — | EP | claimed |
| US-9382237-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| US-9365556-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-9346792-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-05-24 | — | — | US | claimed |
| US-20150105389-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | claimed |
| EP-2852586-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2015-04-01 | — | — | EP | claimed |
| WO-2015042111-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | claimed |
| US-20150080397-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | claimed |
| US-20150080398-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | claimed |
| EP-2834232-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| US-8916555-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-12-23 | — | — | US | claimed |
| US-20130303492-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | claimed |
| US-20130274227-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | US | claimed |
| WO-2013138613-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | claimed |
| WO-2013138617-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | claimed |
| US-20170079954-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-23 | — | — | US | disclosed |
| WO-2013138613-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-1995031452-A1 | THERAPEUTIC PHENOXYALKYLAZOLES AND PHENOXYALKYLAZINES | SANOFI WINTHROP, INC. (US) | 1995-11-23 | — | — | WO | disclosed |